Alexion Pharmaceuticals today announced that the company will report its financial results for the second quarter ended June 30, 2020, before the US financial markets open on July 30, 2020.
Alexion is a recent Algo Engine buy signal from the NASDAQ top 100 group of companies. We’ve added this to our portfolio and will review the upcoming result with close interest.
NASDAQ listed Alexion Pharmaceuticals is now under Algo Engine buy conditions.
May 6, 2020-Alexion Pharmaceuticals announced first quarter 2020 revenues of 1.bn, (27% increase on the same time last year).
On a GAAP basis, diluted EPS in the quarter was $2.50, a 4 percent decrease versus the prior year.
Non-GAAP diluted EPS for the first quarter of 2020 was $3.22, a 35 percent increase versus the first quarter of 2019.